التفاصيل البيبلوغرافية
| العنوان: |
Determination of urinary deanol‐N‐oxide excretion profiles after ingestion of nutritional supplements containing deanol. |
| المؤلفون: |
Krug, Oliver, Guddat, Sven, Görgens, Christian, Piper, Thomas, Möller, Tristan, Thevis, Mario |
| المصدر: |
Drug Testing & Analysis; Nov/Dec2023, Vol. 15 Issue 11/12, p1312-1318, 7p |
| مستخلص: |
2‐(Dimethylamino)ethan‐1‐ol (Deanol) is a widely produced chemical used by both industry and consumers in a variety of applications. Meclofenoxate, a stimulant classified on the World Anti‐Doping Agency Prohibited List, metabolizes into deanol and, presumably, its main metabolite deanol‐N‐oxide. Hence, using liquid chromatography–tandem mass spectrometry, a quantitative detection method for deanol‐N‐oxide in urine was developed. Subsequently, the urinary excretion of deanol‐N‐oxide after oral application of 130 mg of deanol was determined in six volunteers, and urine samples of a cohort of 180 male and female athletes from different sports were analyzed. In addition, urinary deanol‐N‐oxide was determined in an exploratory study with one volunteer ingesting 250 mg of meclofenoxate. The developed test method allowed for limits of detection and quantification for deanol‐N‐oxide at 0.05 and 0.15 μg/mL, respectively. Urinary deanol‐N‐oxide cmax levels were found between 100 and 250 μg/mL 2–5 h post‐administration of 130 mg of deanol. Similarly, urine samples collected after the administration of 250 mg of meclofenoxate exhibited cmax levels of 115 μg/mL. In contrast, deanol‐N‐oxide urine concentrations of pre‐administration specimens and 180 routine doping control urine sample were between 0.3 and 1.3 μg/mL and below limit of quantification and 1.8 μg/mL, respectively. The study suggests that the use of deanol and meclofenoxate results in significantly elevated urinary deanol‐N‐oxide levels. Whether or not monitoring deanol‐N‐oxide in doping controls can support decision‐making processes concerning the detection of meclofenoxate use necessitates further investigations taking into consideration the elimination kinetics of 4‐chlorophenoxyacetic acid, the main metabolite of meclofenoxate, and deanol‐N‐oxide. [ABSTRACT FROM AUTHOR] |
|
Copyright of Drug Testing & Analysis is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder